UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency

UniQure’s announcement follows months of public conflict with FDA leaders over the clinical trial data underpinning its application. The update highlights regulatory and legal risk for the company, but provides no new quantitative details or decision outcome. Market impact is likely limited absent a clearer FDA ruling or submission status.

Analysis

UniQure’s announcement follows months of public conflict with FDA leaders over the clinical trial data underpinning its application. The update highlights regulatory and legal risk for the company, but provides no new quantitative details or decision outcome. Market impact is likely limited absent a clearer FDA ruling or submission status.